BioCardia director granted 8,000 stock options

BioCardia, Inc. director Simon H. Stertzer received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

BioCardia, Inc. director Simon H. Stertzer received a grant of stock options as part of his compensation. He was awarded options to acquire 8,000 shares of BioCardia common stock at an exercise price of $1.20 per share, expiring on July 6, 2036. All of these options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. Following this grant, he holds stock options covering a total of 23,573 shares directly.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider STERTZER SIMON H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 23,573 contracts (Direct)

Footnotes (1)

1. F1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

Key Figures

Stock options granted: 8,000 options Exercise price: $1.20 per share Expiration date: July 6, 2036 +1 more

4 metrics

Stock options granted 8,000 options Grant to director on July 6, 2026

Exercise price $1.20 per share Strike price of granted options

Expiration date July 6, 2036 Option term for 8,000-share grant

Total options after grant 23,573 shares Director’s derivative holdings following transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.2000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-06T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shares are subject to the option vesting and becoming exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) director Simon H. Stertzer report on this Form 4?

Simon H. Stertzer reported receiving a grant of stock options to acquire 8,000 shares of BioCardia common stock. The options were awarded as a compensation-related grant, not an open-market purchase or sale of existing shares.

What are the key terms of the BioCardia (BCDA) stock options granted to Stertzer?

The grant covers 8,000 stock options with an exercise price of $1.20 per share and an expiration date of July 6, 2036. These options give Stertzer the right to buy BioCardia common stock at that fixed price.

When do Simon H. Stertzer’s BioCardia (BCDA) options vest?

One hundred percent of the 8,000 options vest and become exercisable on the one-year anniversary of the grant date. Vesting is conditional on Stertzer continuing as a service provider through that anniversary date.

How many BioCardia (BCDA) derivative securities does Stertzer hold after this grant?

After this grant, Stertzer holds derivative securities representing 23,573 shares of BioCardia common stock. This total reflects his stock option position following the 8,000-option award reported in the filing.

Was the BioCardia (BCDA) Form 4 transaction a market buy or sell?

No, the transaction was a compensation-related stock option grant coded as an acquisition. It did not involve an open-market purchase or sale of BioCardia common stock by Stertzer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 10:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STERTZER SIMON H

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.2	07/06/2026		A		8,000		(1)	07/06/2036	Common stock	8,000	$0	23,573	D

Explanation of Responses:

1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)